Functional evaluation of FKBP family protein and alpha thalassemia

FK506-binding proteins (FKBPs) have become the subject of considerable interest in several fields, leading to the identification of several cellular and molecular pathways. Over the past few years, FKBPs have emerged as a potential therapeutic target for a wide range of endocrine- and cardiovascular-related diseases. As a result, several researchers have focused on determination and development of novel therapeutic drugs that target FKBPs. This book, therefore, analyzes the differences between mammalian and Drosophila FKBPs function in relation to the immunosuppressant drugs, FK506, and rapamycin. Again, hemoglobinopathies may have an impact on the red cell indices, and these are critical to the diagnosis of thalassemias. The key components of the complete blood count have been used in the diagnosis of +-thalassemia. That is the mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH) and red blood cell counts (RBC) could, therefore, be used as a threshold to classify individuals into suspected and non +-thalassemic respectively.